Theratechnologies Inc. (Theratechnologies) is a Canada-based biopharmaceutical company that discovers or acquires therapeutic products for development and commercialization targeting unmet medical needs. The Company’s advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor. During the fiscal year ended November 30, 2008 (fiscal 2008), it completed a confirmatory Phase III clinical trial evaluating tesamorelin in human immunodeficiency virus (HIV)-associated lipodystrophy, a serious metabolic disorder involving excess abdominal fat.